Mujumdar Vaidehi, Huang Marilyn, Smith Lindsey Chippendale, Musa Fernanda
Atrium Health Levine Cancer Institute, 1021 Morehead Drive, Suite 2100, Charlotte, NC 28202, USA.
University of Virginia School of Medicine, P.O. Box 800712, Charlottesville, VA 22908, USA.
Gynecol Oncol Rep. 2025 Jul 11;60:101803. doi: 10.1016/j.gore.2025.101803. eCollection 2025 Aug.
•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin's safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.
•伊维菌素于1996年被美国食品药品监督管理局（FDA）批准为治疗肠道类圆线虫病和盘尾丝虫病的口服药物。
•关于伊维菌素作为一种妇科抗癌化合物的数据尚缺。
•关于伊维菌素在癌症治疗中的临床研究仅限于在细胞系中观察到的效果。
•我们尚未评估伊维菌素在妇科癌症中的安全性和疗效。
•我们不推荐且强烈告诫不要使用伊维菌素治疗妇科癌症。
